Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is well-positioned for commercial expansion through their BEACON study which showed significant improvements in cognitive and neuropsychiatric symptoms in patients using ZUNVEYL. Additionally, their CONVERGE and RESOLVE studies, as well as their long-term care commercial team and potential licensing partnerships, provide strong potential for long-term market uptake. With positive financial results and an early settlement agreement that eliminates future royalty and milestone payment obligations, Alpha Cognition is set for success in the long term.

Bears say

Alpha Cognition is valued at $580M utilizing a DCF-based valuation methodology with a 12-month price objective of $20 per share. Risks include potential delays in achieving sales traction for ZUNVEYL, slower market uptake due to pricing pressures or competition, setbacks in clinical testing, and possible dilution risk. The company's pipeline initiatives, specifically a sublingual benzgalantamine formulation, may add value to the company's product portfolio and broaden the addressable market for ZUNVEYL, but these forecasts do not currently include any contribution from this asset.

ACOG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 5 analysts, ACOG has a Strong Buy consensus rating as of Aug 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.